HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gerber reboots whey protein formula petition

This article was originally published in The Tan Sheet

Executive Summary

Nestle Infant Nutrition asks FDA to allow a qualified health claim that 100-percent whey-protein partially hydrolyzed infant formula "may reduce the risk of developing the most common allergic disease of infancy -- atopic dermatitis" in infants not exclusively breastfed. The subsidiary of Florham Park, N.J.-based Gerber Products adds in a May 14 citizen 1petition that partially hydrolyzed formulas are not meant to treat existing food allergy symptoms. FDA posted the petition July 21. In 2005, FDA denied a request by Nestle Infant Nutrition, then a Nestle USA division, for a food allergy QHC for whey protein formula (2"The Tan Sheet" May 22, 2006). The firm says its resubmitted petition has a reworded claim and includes additional supporting science

You may also be interested in...

FDA Denies Claim Linking Hydrolyzed Infant Formula To Reduced Allergies

There is "no credible scientific evidence" to support a qualified health claim linking consumption of 100% partially hydrolyzed whey protein infant formula (PHF-W) to a reduced risk of the development of food allergies, FDA concludes in a May 11 letter to petitioner Nestlé USA

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts